{"analyses":[{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"3.97","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0090","paramType":"Difference in LS Mean","paramValue":"2.35","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-1.55","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.56","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.4987","paramType":"Difference in LS Mean","paramValue":"0","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"0.68","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"3.92","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0100","paramType":"Difference in LS Mean","paramValue":"2.3","statisticalMethod":"MMRM analysis; 1-sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.97","upperLimit":"1.27","value":"0.15"},{"groupId":"OG001","lowerLimit":"1.32","upperLimit":"3.67","value":"2.50"},{"groupId":"OG002","lowerLimit":"-0.94","upperLimit":"1.24","value":"0.15"},{"groupId":"OG003","lowerLimit":"1.28","upperLimit":"3.62","value":"2.45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"27"}],"units":"Participants"}],"description":"FAACT-5IASS is a 5-item subscale to measure participants' perceptions of anorexia (appetite) concerns for past 7 days. Each item was scored from 0 to 4, where 0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, and 4= very much. The total FAACT-5IASS score ranged from 0 to 20. Higher scores are associated with a higher health-related quality of life. FAACT-5IASS was analyzed using an MMRM model.","dispersionType":"90% Confidence Interval","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","timeFrame":"Baseline (prior to dose on Day 1), Week 12","title":"Part A: Change From Baseline in FAACT- 5-Item Anorexia Symptom Scale (5IASS) at Week 12","type":"SECONDARY","unitOfMeasure":"Units on a scale"}